Cover Image
市場調查報告書

全球免疫學的醫藥品市場預測

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

出版商 GBI Research 商品編碼 516017
出版日期 內容資訊 英文 181 Pages
訂單完成後即時交付
價格
Back to Top
全球免疫學的醫藥品市場預測 Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs
出版日期: 2018年03月31日 內容資訊: 英文 181 Pages
簡介

全球免疫學的醫藥品市場,預計從2015年的577億美元,擴大到2022年的754億美元。

本報告提供全球免疫學的醫藥品市場相關調查分析,主要上市產品,開發平台形勢的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 主要上市產品

  • 概要
  • Humira (adalimumab)
  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Rituxan (rituximab)
  • Stelara (ustekinumab)
  • Simponi (golimumab)
  • Prograf (tacrolimus)
  • Cimzia (certolizumab pegol)
  • Entyvio (vedolizumab)
  • Cosentyx (Secukinumab)

第4章 開發平台形勢的評估

  • 概要
  • 開發平台的開發形勢
  • 開發平台的分子標的
  • 臨床試驗
  • 結論

第5章 複數方案的市場預測

  • 市場規模全體
  • 學名藥的普及
  • 收益預測:各分子標的

第6章 企業分析與定位

  • 收益與市場佔有率分析:各企業
  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 授權交易
  • 共同開發交易

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GBIHC472MR

Summary:

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response. The following report covers all immunology disorders, with a particular focus on four key areas: rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD) and transplant rejection/graft versus host disease (GVHD).

Immunology drugs market is projected to grow to $113 billion in 2023, at a compound annual growth rate (CAGR) of over 8%. The market size in the US is expected to increase at a CAGR of 6.58%, therefore accounting for approximately half of the global immunology market.

The prevalence populations of many indications within immunology are increasing, which is one of the major drivers of the expected market growth. For example, the prevalence population of RA across the seven major markets is expected to increase from 6.11 million in 2016 to 6.66 million in 2023.

Immunology market contains a number of blockbuster drugs, most of which are mAbs that target tumor necrosis alpha (TNF-α), a key pro-inflammatory cytokine. These include Humira (adalimumab), the most successful drug industry-wide, as well as Remicade (infliximab), Rituxan (rituximab), Simponi (golimumab) and Cimzia (certolizumab pegol). However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced dominance.

The first TNF biosimilars were approved several years ago when the first patents expired, but they are only now starting to have an impact on the revenue of their premium counterparts. For example, Remsima and Inflectra are Remicade biosimilars that have been approved in the EU, and Inflectra also has FDA approval to be marketed in 2018 when the patent for Remicade expires in the US. These biosimilars are exerting a very noticeable impact on Remicade's revenue, which peaked in 2014 at $9.9 billion but is expected to fall to $3 billion by 2023.

Furthermore, there are also several drugs that have recently been approved - such as Cosentyx and Otezla - and several in late-stage pipeline development - such as, filgotinib, AR-101 and upadacitinib tartrate - that are expected to become blockbuster drugs over the forecast period, generating further market growth within immunology.

The report "Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs" provides the following -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
  • Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Scope:

The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.

Overall, there are 2,070 immunology products in the pipeline.

  • Which molecular targets are most prominent within the pipeline?
  • How do the key indications differ in terms of molecule type?
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?
  • The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
  • Which products will contribute to market growth most, and which will achieve blockbuster status?
  • Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
  • What CAGR will these companies register in the forecast period?
  • How many strategic consolidations have been completed in the past decade?
  • Which types of assets attract the largest deal values?

Reasons to buy:

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
  • Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
  • Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Overview
    • 2.1.1. Rheumatoid Arthritis
    • 2.1.2. Psoriasis
    • 2.1.3. Inflammatory Bowel Disease
    • 2.1.4. Graft Versus Host Disease and Transplant Rejection
  • 2.2. Symptoms
  • 2.3. Diagnosis
    • 2.3.1. Rheumatoid Arthritis
    • 2.3.2. Psoriasis
    • 2.3.3. Inflammatory Bowel Disease
    • 2.3.4. Graft Versus Host Disease and Transplant Rejection
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Rheumatoid Arthritis
    • 2.4.2. Psoriasis
    • 2.4.3. Inflammatory Bowel Disease
    • 2.4.4. Graft Versus Host Disease and Transplant Rejection
  • 2.5. Epidemiology
    • 2.5.1. Rheumatoid Arthritis
    • 2.5.2. Psoriasis
    • 2.5.3. Inflammatory Bowel Disease
    • 2.5.4. Graft Versus Host Disease and Transplant Rejection
  • 2.6. Co-morbidities and Complications
  • 2.7. Treatment
    • 2.7.1. Rheumatoid Arthritis
    • 2.7.2. Psoriasis
    • 2.7.3. Inflammatory Bowel Disease
    • 2.7.4. Graft-Versus-Host Disease and Transplant Rejection

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Humira (adalimumab) - AbbVie
  • 3.3. Enbrel (etanercept) - Amgen
  • 3.4. Remicade (infliximab) - Johnson & Johnson
  • 3.5. Rituxan (rituximab) - Roche
  • 3.6. Stelara (ustekinumab) - Johnson & Johnson
  • 3.7. Simponi (golimumab) - Johnson & Johnson
  • 3.8. Orencia (abatacept) - Bristol-Myers Squibb
  • 3.9. Tysabri (natalizumab) - Biogen
  • 3.10. Actemra (tocilizumab) - Roche
  • 3.11. Prograf (tacrolimus) - Astellas
  • 3.12. Cimzia (certolizumab) - UCB
  • 3.13. Entyvio (vedolizumab) - Takeda
  • 3.14. Cosentyx (secukinumab) - Novartis
  • 3.15. Otezla (apremilast) - Celgene
  • 3.16. Xeljanz (tofacitinib) - Pfizer
  • 3.17. Taltz (ixekizumab) - Eli Lilly

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Cumulative Clinical Program Size
  • 4.5. Assessment of Key Late-Stage Pipeline Products
    • 4.5.1. Filgotinib - Galapagos and Gilead Sciences
    • 4.5.2. AR-101-Aimmune Therapeutics
    • 4.5.3. Upadacitinib tartrate - AbbVie
    • 4.5.4. Lanadelumab - Shire
    • 4.5.5. Ozanimod hydrochloride - Celgene
    • 4.5.6. Risankizumab - AbbVie
  • 4.6. Conclusion

5. Multi-scenario Market Forecast to 2023

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Cytokines and Cytokine Receptors
    • 5.3.2. Intracellular Signal Transducers
    • 5.3.3. Cell Surface Antigens
    • 5.3.4. Intercellular Interaction and Adhesion Molecules

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. AbbVie
    • 6.1.2. Johnson & Johnson
    • 6.1.3. Novartis
    • 6.1.4. Pfizer
    • 6.1.5. Roche
    • 6.1.6. Amgen
    • 6.1.7. Celgene
    • 6.1.8. Eli Lilly
  • 6.2. Company Landscape
  • 6.3. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Indication
    • 7.1.3. Deals by Stage of Development
    • 7.1.4. Deals by Molecule Type, Molecular Target and Value
    • 7.1.5. Table for Licensing Deals with Disclosed Values
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Indication
    • 7.2.3. Deals by Stage of Development
    • 7.2.4. Deals by Molecule Type, Molecular Target and Value
    • 7.2.5. Table for Co-development Deals with Disclosed Values

8. Appendix

  • 8.1. References
  • 8.2. Figures of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Immunology Drugs Market, Global, Symptoms of RA, Psoriasis and IBD, 2018
  • Table 2: Immunology Drugs Market, Global, Organ-Specific Symptoms of Transplant Rejection, 2018
  • Table 3: Immunology Drugs Market, Global, Organ-Specific Symptoms of Acute GVHD, 2018
  • Table 4: Immunology Drugs Market, Global, Organ-Specific Symptoms of Chronic GVHD, 2018
  • Table 5: Immunology Drugs Market, Etiology of RA, Psoriasis, IBD and GVHD, 2018
  • Table 6: Immunology Drugs Market, 7MM, Epidemiology of Key Immunology Indications, 2018
  • Table 7: Immunology Drugs Market, Global, Approved Indications for Humira, 2018
  • Table 8: Immunology Drugs Market, Global, Approved Indications for Enbrel, 2018
  • Table 9: Immunology Drugs Market, Global, Approved Indications for Remicade, 2018
  • Table 10: Immunology Drugs Market, Global, Approved Indications for Rituxan, 2018
  • Table 11: Immunology Drugs Market, Global, Approved Indications for Stelara, 2018
  • Table 12: Immunology Drugs Market, Global, Approved Indications for Simponi, 2018
  • Table 13: Immunology Drugs Market, Global, Approved Indications for Orencia, 2018
  • Table 14: Immunology Drugs Market, Global, Approved Indications for Tysabri, 2018
  • Table 15: Immunology Drugs Market, Global, Approved Indications for Actemra, 2018
  • Table 16: Immunology Drugs Market, Global, Approved Indications for Prograf, 2018
  • Table 17: Immunology Drugs Market, Global, Approved Indications for Cimzia, 2018
  • Table 18: Immunology Drugs Market, Global, Approved Indications for Entyvio, 2018
  • Table 19: Immunology Drugs Market, Global, Approved Indications for Cosentyx, 2018
  • Table 20: Immunology Drugs Market, Global, Approved Indications for Otezla, 2018
  • Table 21: Immunology Drugs Market, Global, Approved Indications for Xeljanz, 2018
  • Table 22: Immunology Drugs Market, Global, Approved Indications for Taltz, 2018
  • Table 23: Immunology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023
  • Table 24: Immunology Drugs Market, Global, Usage of Generics Across Key Indications, 2018
  • Table 25: Immunology Drugs Market, Global, Forecast Revenue by Company (%), 2016-2023

List of Figures

  • Figure 1: Immunology Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2016-2023
  • Figure 2: Immunology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2016-2023
  • Figure 3: Immunology Drugs Market, 7MM, Epidemiology Patterns for Crohn's Disease, 2016-2023
  • Figure 4: Immunology Drugs Market, Epidemiology Patterns for Ulcerative colitis, 2016-2023
  • Figure 5: Immunology Drugs Market, Epidemiology Patterns for Graft Versus Host Disease, 2016-2023
  • Figure 6: Immunology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
  • Figure 7: Immunology Drugs Market, Global, Annual Revenues for Humira ($bn), 2006-2023
  • Figure 8: Immunology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2023
  • Figure 9: Immunology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2023
  • Figure 10: Immunology Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2023
  • Figure 11: Immunology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023
  • Figure 12: Immunology Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2023
  • Figure 13: Immunology Drugs Market, Global, Annual Revenue for Orencia ($bn), 2006-2023
  • Figure 14: Immunology Drugs Market, Global, Annual Revenue for Tysabri ($bn), 2006-2023
  • Figure 15: Immunology Drugs Market, Global, Annual Revenues for Actemra ($bn), 2006-2023
  • Figure 16: Immunology Drugs Market, Global, Annual Revenue for Prograf ($bn), 2006-2023
  • Figure 17: Immunology Drugs Market, Global, Annual Revenue for Cimzia ($bn), 2008-2023
  • Figure 18: Immunology Drugs Market, Global, Annual Revenue for Entyvio ($bn), 2014-2023
  • Figure 19: Immunology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2023
  • Figure 20: Immunology Drugs Market, Global, Annual Revenue for Otezla($bn), 2014-2023
  • Figure 21: Immunology Drugs Market, Global, Annual Revenues for Xeljanz ($bn), 2012-2023
  • Figure 22: Immunology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016-2023
  • Figure 23: Immunology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
  • Figure 24: Immunology Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2018
  • Figure 25: Immunology Drugs Market, Global, Pipeline by Program Type, 2018
  • Figure 26: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2018
  • Figure 27: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2018
  • Figure 28: Immunology Drugs Market, Pipeline by Molecular Target, 2018
  • Figure 29: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2018
  • Figure 30: Immunology Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018
  • Figure 31: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2017
  • Figure 32: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2017
  • Figure 33: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2017
  • Figure 34: Immunology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017
  • Figure 35: Immunology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2017
  • Figure 36: Immunology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2017
  • Figure 37: Immunology Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2017
  • Figure 38: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017
  • Figure 39: Immunology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2017
  • Figure 40: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017
  • Figure 41: Immunology Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2017
  • Figure 42: Immunology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017
  • Figure 43: Immunology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2017
  • Figure 44: Immunology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2017
  • Figure 45: Immunology Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2017
  • Figure 46: Immunology Drugs Market, Global, Annual Revenue Forecast for Filgotinib ($m), 2019-2023
  • Figure 47: Immunology Drugs Market, Global, Annual Revenue Forecast for AR-101 ($m), 2019-2023
  • Figure 48: Immunology Drugs Market, Global, Annual Revenue Forecast for Upadacitinib ($m), 2019-2023
  • Figure 49: Immunology, Global, Annual Revenue Forecast for Lanadelumab ($m), 2018-2023
  • Figure 50: Immunology Drugs Market, Global, Annual Revenue Forecast for Ozanimod ($m), 2018-2023
  • Figure 51: Immunology Drugs Market, Global, Annual Revenue Forecast for Risankizumab ($m), 2018-2023
  • Figure 52: Immunology Drugs Market, Global, Market Size ($bn), 2016-2023
  • Figure 53: Immunology Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016-2023
  • Figure 54: Immunology Drugs Market, Global, Annual Revenue Forecast for Cytokines and Cytokine Receptors ($bn), 2016-2023
  • Figure 55: Immunology Drugs Market, Global, Annual Revenue Forecast for Intracellular Signal Transducers ($bn), 2016-2023
  • Figure 56: Immunology Drugs Market, Global, Annual Revenue Forecast for Cell Surface Antigens ($bn), 2016-2023
  • Figure 57: Immunology Drugs Market, Global, Annual Revenue Forecast for Intercellular Interaction and Adhesion Molecules ($bn), 2016-2023
  • Figure 58: Immunology Drugs Market, Global, Company Analysis Matrix, 2016-2023
  • Figure 59: Immunology Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023
  • Figure 60: Immunology Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
  • Figure 61: Immunology Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
  • Figure 62: Immunology Drugs Market, Global, Revenues by Route of Acquisition, 2016-2023
  • Figure 63: Immunology Drugs Market, Global, AbbVie, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 64: Immunology Drugs Market, Global, Johnson & Johnson, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 65: Immunology Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2016-2023
  • Figure 66: Immunology Drugs Market, Global, Pfizer, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 67: Immunology Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
  • Figure 68: Immunology Drugs Market, Global, Amgen, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 69: Immunology Drugs Market, Global, Celgene, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 70: Immunology Drugs Market, Global, Eli Lilly, Annual Revenue Forecast ($bn), 2016-2023
  • Figure 71: Immunology Drugs Market, Global, High-Activity and Late-Stage Pipeline Developers by Company Type, 2018
  • Figure 72: Immunology Drugs Market, Global, Pipeline, High-Activity and Late-Stage Pipeline Developers by Level of Specialization, 2018
Back to Top